Global Trial Reveals Multi-Strain Probiotic Successfully Prevents Bacterial Vaginosis Recurrence by Restoring Vaginal Microbiome

New VIBRANT trial data shows a multi-strain probiotic can restore protective vaginal bacteria, reducing BV recurrence and lowering HIV risks for women.

By: AXL Media

Published: Mar 19, 2026, 4:41 AM EDT

Source: Information for this report was sourced from Mass General Brigham

Addressing a Global Crisis in Women’s Health

Bacterial vaginosis (BV) is a pervasive condition affecting approximately 30% of women worldwide, characterized by a disruption of the delicate vaginal microbiome. While antibiotics are the standard treatment for clearing immediate infections, they often fail to restore the beneficial bacteria necessary to maintain a healthy environment, leading to a 60% recurrence rate within six months. Beyond disruptive symptoms like odor and irritation, chronic BV is linked to severe outcomes, including preterm birth and an increased susceptibility to HIV and cervical cell abnormalities. Researchers from Mass General Brigham and CAPRISA are now challenging this cycle by introducing a multi-strain probiotic designed to stay in the body long after the initial treatment ends.

The Strategic Shift to Multi-Strain Therapy

Previous attempts to stabilize the vaginal microbiome focused on single-strain probiotics, but these biotherapeutics frequently failed to remain colonized in more than half of the participants. To overcome this, the VIBRANT (Vaginal lIve Biotherapeutic RANdomized Trial) team developed a more robust product containing up to 15 different strains of Lactobacillus crispatus. This "multi-strain" approach was designed to create a more resilient bacterial community that could better compete with harmful microorganisms. By providing a diverse population of protective bacteria, the therapy aims to help the body maintain its own health independently, reducing the long-term reliance on repeated courses of antibiotics.

Promising Results from the VIBRANT Trial

The phase 1 trial involved 90 participants across Boston and rural South Africa, who received either a placebo, a 6-strain tablet, or a 15-strain tablet following a standard course of antibiotics. Using advanced genetic sequencing, the research team tracked the presence of beneficial bacteria over 12 weeks. The findings, published in Cell Host & Microbe, were highly encouraging: two-thirds of the participants successfully established a protective bacterial community within the first five weeks. Even more significantly, nearly half of those colonized retained the beneficial bacteria through the 12-week follow-up period, even if they had only received three days of active treatment.